Armata Pharmaceuticals (ARMP) Q3 2025 earnings summary

Executive summary

• Focused on developing bacteriophage therapeutics for antibiotic-resistant bacterial infections, with lead candidates AP-PA02 and AP-SA02 advancing through clinical trials and positive Phase 2a results for AP-SA02 in S. aureus bacteremia.

• Fully commissioned a state-of-the-art cGMP manufacturing facility in Los Angeles to support future clinical trials and commercialization.

• Entered into $15 million August 2025 Credit Agreement to advance AP-SA02 development.

• Existing cash and cash equivalents of $14.8 million as of September 30, 2025, insufficient to fund operations for the next 12 months, raising substantial doubt about ability to continue as a going concern.

Financial highlights

• Net loss of $26.7 million for Q3 2025, compared to $5.5 million in Q3 2024, impacted by a $14.6 million negative change in fair value of the Convertible Loan.

• Grant and award revenue was $1.2 million for Q3 2025, down from $3.0 million in Q3 2024; $3.8 million for the nine months, nearly flat year-over-year.

• Operating expenses decreased to $8.9 million in Q3 2025 from $12.7 million in Q3 2024, with R&D expenses at $5.8 million and G&A at $3.1 million.

• Interest expense increased to $4.3 million in Q3 2025 from $2.9 million in Q3 2024, and to $11.8 million for the nine months from $7.5 million year-over-year.

• Loss from operations was $7.8 million, improved from $9.8 million in Q3 2024.

Outlook and guidance

• Plans to initiate a pivotal Phase 3 trial for AP-SA02 in 2026, subject to FDA feedback.

• Ongoing efforts to secure additional funding through equity, debt, grants, or strategic partnerships; failure to raise capital may result in curtailment of operations.

• Committed to U.S.-based manufacturing and supporting federal supply chain security initiatives.

• Focused on advancing current product candidates and seeking regulatory approval; no expectation of product revenue until at least one candidate is approved.